KR20000064765A - 케모카인 알파 ２ - Google Patents

케모카인 알파 ２ Download PDF

Info

Publication number
KR20000064765A
KR20000064765A KR1019980707528A KR19980707528A KR20000064765A KR 20000064765 A KR20000064765 A KR 20000064765A KR 1019980707528 A KR1019980707528 A KR 1019980707528A KR 19980707528 A KR19980707528 A KR 19980707528A KR 20000064765 A KR20000064765 A KR 20000064765A
Authority
KR
South Korea
Prior art keywords
polypeptide
ckα
amino acid
seq
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019980707528A
Other languages
English (en)
Korean (ko)
Inventor
지안 니
라이너 엘 겐츠
제프리 와이 수
하오동 리
Original Assignee
벤슨 로버트 에이치.
휴먼 게놈 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벤슨 로버트 에이치., 휴먼 게놈 사이언시즈, 인코포레이티드 filed Critical 벤슨 로버트 에이치.
Publication of KR20000064765A publication Critical patent/KR20000064765A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
KR1019980707528A 1996-03-19 1997-03-19 케모카인 알파 ２ Ceased KR20000064765A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1365396P 1996-03-19 1996-03-19
US60/013,653 1996-03-19
PCT/US1997/004329 WO1997035010A1 (en) 1996-03-19 1997-03-19 Chemokine alpha 2

Publications (1)

Publication Number Publication Date
KR20000064765A true KR20000064765A (ko) 2000-11-06

Family

ID=21761043

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980707528A Ceased KR20000064765A (ko) 1996-03-19 1997-03-19 케모카인 알파 ２

Country Status (9)

Country Link
US (3) US5910431A (enExample)
EP (1) EP0896622A4 (enExample)
JP (1) JP2000507101A (enExample)
KR (1) KR20000064765A (enExample)
CN (1) CN1217024A (enExample)
AU (1) AU733603B2 (enExample)
CA (1) CA2249997A1 (enExample)
NZ (1) NZ332318A (enExample)
WO (1) WO1997035010A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410268B1 (en) * 1996-03-18 2002-06-25 Human Genome Sciences, Inc. Polynucleotides encoding chemokine alpha-3
NZ332318A (en) * 1996-03-19 2000-10-27 Human Genome Sciences Inc Chemokine alpha 2 and it's therapeutic and diagnostic use in treating illnesses
AU6132698A (en) * 1997-01-23 1998-08-18 Schering Corporation Mammalian chemokines; receptors; reagents; uses
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
AU1824499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Human cxc chemokine ((tim-1))
CA2320144A1 (en) * 1998-02-10 1999-08-12 Millennium Pharmaceuticals, Inc. Neokine protein and nucleic acid molecules and uses therefor
US6573095B1 (en) 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US20040258710A1 (en) * 1999-03-08 2004-12-23 Genentech, Inc. Novel polypeptides and nucleic acids encoding Bolekine
US20030096411A1 (en) * 1999-12-07 2003-05-22 George Michalopoulos Novel long-term three-dimensional tissue culture system
US6737270B1 (en) 1999-12-07 2004-05-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education Long-term three dimensional tissue culture system
CN1329090A (zh) * 2000-06-21 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人自身免疫疾病相关蛋白10和编码这种多肽的多核苷酸
US20040151729A1 (en) * 2002-10-28 2004-08-05 George Michalopoulos Novel long-term three-dimensional culture system
US7648509B2 (en) 2003-03-10 2010-01-19 Ilion Medical Llc Sacroiliac joint immobilization
US20090024174A1 (en) * 2007-07-17 2009-01-22 Stark John G Bone screws and particular applications to sacroiliac joint fusion
US8740912B2 (en) 2008-02-27 2014-06-03 Ilion Medical Llc Tools for performing less invasive orthopedic joint procedures

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897348A (en) * 1983-08-25 1990-01-30 Sri International Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
US4897346A (en) * 1986-07-15 1990-01-30 Beckman Instruments, Inc. Stabilized liquid enzyme composition for glucose determination
US5212073A (en) * 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
CA2064558C (en) * 1989-09-25 2001-01-30 Ian B. Pragnell Method for inhibiting growth of stem cells
WO1992006196A1 (en) * 1990-09-28 1992-04-16 Cetus Oncology Corporation Gro genes, proteins, and uses thereof
US5266302A (en) 1990-10-03 1993-11-30 Peyman Gholam A Method of performing angiography
US6001649A (en) * 1990-11-29 1999-12-14 Societe Anonyme: Elf Sanofi Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US5346686A (en) * 1992-10-05 1994-09-13 Mallinckrodt Medical, Inc. Labelled interleukin-8 and medical uses thereof
EP0804486B1 (en) * 1992-11-27 2008-10-01 Laboratoires Serono SA Granulocyte chemotactic protein
JP2879303B2 (ja) * 1993-01-14 1999-04-05 佑 本庶 ｃＤＮＡライブラリーの作製方法、および新規なポリペプチドとそれをコードするＤＮＡ
EP0679716A4 (en) * 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
US5504003A (en) * 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
US5633149A (en) * 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US5605817A (en) * 1995-01-19 1997-02-25 Incyte Pharmaceuticals, Inc. DNA encoding chemokine expressed in fetal spleen
EP0811059A4 (en) * 1995-02-08 1998-04-01 Human Genome Sciences Inc HUMAN CHEMOKINE BETA-11 AND ALPHA-1
NZ332318A (en) 1996-03-19 2000-10-27 Human Genome Sciences Inc Chemokine alpha 2 and it's therapeutic and diagnostic use in treating illnesses
CA2248653C (en) 1996-05-01 2003-08-12 Genitope Corporation Vaccines for treatment of lymphoma and leukemia
US6222276B1 (en) * 1998-04-07 2001-04-24 International Business Machines Corporation Through-chip conductors for low inductance chip-to-chip integration and off-chip connections

Also Published As

Publication number Publication date
AU2333097A (en) 1997-10-10
WO1997035010A8 (en) 2004-06-03
NZ332318A (en) 2000-10-27
US7122639B2 (en) 2006-10-17
JP2000507101A (ja) 2000-06-13
AU733603B2 (en) 2001-05-17
CN1217024A (zh) 1999-05-19
US6479633B1 (en) 2002-11-12
US20030082748A1 (en) 2003-05-01
EP0896622A1 (en) 1999-02-17
WO1997035010A1 (en) 1997-09-25
US5910431A (en) 1999-06-08
CA2249997A1 (en) 1997-09-25
EP0896622A4 (en) 2004-11-03

Similar Documents

Publication Publication Date Title
JP2001501453A (ja) ヒト腫瘍壊死因子δおよびε
US7094564B1 (en) Human tumor necrosis factor receptor
WO1997033899A1 (en) Apoptosis inducing molecule i
US6458349B1 (en) Chemokine β-4 polypeptides
KR20000064765A (ko) 케모카인 알파 ２
EP0832233B1 (en) Human chemokine beta-13
KR19990022283A (ko) 인체 케모킨 베타-11 및 인체 케모킨 알파-1
US5866373A (en) Polynucleotide encoding a human chemotactic protein
JP2001524818A (ja) ケモカインβ−６
WO1996039520A1 (en) Human chemokine beta-12
US7419662B2 (en) Methods of making chemokine alpha 3 antibodies
US6130061A (en) Human stem cell antigen 2
JP3759168B2 (ja) 内皮単球活性ポリペプチドｉｉｉ
AU753730B2 (en) Human chemokine beta-13
US20060171918A1 (en) Apoptosis inducing molecule I
KR100490707B1 (ko) 사람의종양괴사인자델타및엡실론
AU767338B2 (en) Chemokine alpha 2
US20060073573A1 (en) Chemotactic cytokine III
WO1997023640A1 (en) Human chemotactic cytokine i
KR19990087164A (ko) 사람 케모킨 폴리펩티드
WO2001030828A1 (en) Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2)
JP2000506366A (ja) ケモカインアルファ３
JP2008194038A (ja) ヒト腫瘍壊死因子δおよびε

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19980919

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20020319

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040130

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20040413

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20040130

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I